Table 4. Association of clinical variables and RasGRP3 protein expression with cancer-specific survival based on Cox proportional hazards regression models.
| Variable |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | Adjusted HR (95% CI) | Adjusted P-value | |
| Preoperative PSA | ||||
| <10 vs ⩾10 | 0.927 (0.496–1.734) | 0.813 | 0.687 (0.254–1.859) | 0.459 |
| Gleason score | ||||
| ⩽6 vs ⩾7 | 2.222 (1.019–4.848) | 0.045 | 1.461 (0.675–3.162) | 0.336 |
| T stage | ||||
| ⩽2 vs ⩾3 | 2.260 (1.126–4.536) | 0.022 | 1.162 (0.452–2.992) | 0.755 |
| Lymph node status | ||||
| Positive vs negative | 1.328 (0.691–2.554) | 0.395 | 0.574 (0.263–1.254) | 0.164 |
| Surgical margin status | ||||
| Positive vs negative | 1.644 (0.873–3.097) | 0.124 | 1.807 (0.780–4.189) | 0.168 |
| RasGRP3 expression | ||||
| Positive vs negative | 7.798 (4.142–17.983) | <0.001 | 7.536 (4.405–16.015) | 0.003 |
Abbreviations: CI, confidence interval; HR, hazard ratio; RasGRP3, guanyl nucleotide-releasing protein for Ras 3.